Format

Send to

Choose Destination
See comment in PubMed Commons below
Transfus Clin Biol. 2011 Dec;18(5-6):527-35. doi: 10.1016/j.tracli.2011.09.001. Epub 2011 Oct 22.

Relevance of RH variants in transfusion of sickle cell patients.

Author information

1
Établissement français du sang Île-de-France, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94017 Créteil, France. france.noizat-pirenne@efs.sante.fr

Abstract

Transfusion remains the main treatment of sickle cell disease patients. Red cell alloimmunization is frequent because of the antigen disparities between patients of African descent and donors of European ancestry. Alloimmunization is associated with severe hemolytic transfusion reaction, autoantibody formation, and difficulties in the management of transfusion compatibility. Beside common antigens, a number of different RH variant antigens found in individuals of African descent can be involved in alloimmunization. If some variants, such as Hr(S) negative antigens, are known to prone significant alloantibodies and delayed hemolytic transfusion reactions, it is not clear whether all the described variants represent a clinical risk for sickle cell disease patients. The knowledge of the clinical relevance of RH variants is a real issue. An abundance of molecular tools are developed to detect variants, but they do not distinguish those likely to prone immunization from those that are unlikely to prone immunization and delayed hemolytic transfusion reactions. A strategy of prevention, which generally requires rare red blood cells, cannot be implemented without this fundamental information. In this review, we discuss the relevance of RH variants in sickle cell disease, based on the published data and on our experience in transfusion of these patients.

PMID:
22024128
DOI:
10.1016/j.tracli.2011.09.001
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center